HealthTree Resources
Posted by 
Last updated and reviewed on: October 13, 2025We invite you to read the sources below to learn more about CAR T-cell therapy for multiple myeloma.
News articles and pages
- Real-World CAR T Data for Extramedullary Patients
- What’s Better for High-Risk Multiple Myeloma? Cilta-cel vs Standard of Care
- The Use of Bispecifics and CAR-T in Myeloma Treatment
- Two Myeloma CAR T Therapies Receive FDA Approval for Earlier Use
- New Target for Relapsed Myeloma: LILRB4-directed CAR-T Therapy
- How CAR-T Therapy is Changing the Treatment Landscape for Myeloma
- An ODAC Meeting for Carvykti (CAR-T) for Multiple Myeloma Treatment Announced
- Cell Features Key to Targeting Myeloma Cells: BCMA Directed Therapies
- Could CAR-T Therapy Be Given By Direct Injection?
- Physicians Take on CAR-T Therapy Secondary Cancer Risks
- CAR T Therapy Gets First European Approval in Earlier Lines for Multiple Myeloma
- An ODAC Meeting for Abecma (CAR-T) for Triple-Class Exposed Multiple Myeloma
- My CAR-T Therapy Experience: A Myeloma Patient Story
- ASH 2023: How Can Relapsed/Refractory Myeloma Outcomes Improve in 2024?
- ASH 2023: The Effect of Stem Cell Infusion on ICAHT after CAR-T Cell Therapy
- ASH 2023: Raising the BCMA Standard in Multiple Myeloma
HealthTree University (HTU) videos
- Myeloma CAR-T UNIT
- How are IMiDs and CELMoDs being explored in combination with CAR T-cell therapy?
- What is being done to enhance the response of CAR-T cell therapy and bispecific antibody therapy?
- What factors should be considered when choosing between a CAR T cell therapy and a bispecific antibody therapy?
- What types of infections have been seen with CAR-T and BsAb therapy? Why are these infections prevalent? How are serious infections mitigated after CAR T cell and BsAb therapy?
- HTU Myeloma Specialist Conference Interviews on CAR-T
- Building a Myeloma-Specific Score to Predict CAR-T Therapy Toxicities | Utkarsh Goel MD
- Update on BMS-986393, a GPRC5D #Myeloma CAR-T | Susan Bal, MD
- Treating High-Risk Smoldering Myeloma using CAR-T - CAR-PRISM Study | Omar Nadeem, MD
- Post-CAR-T Driving Restrictions after Week 4 In Myeloma Appear Unnecessary | Rahul Banerjee
- Beating T-Cell Exhaustion: The Future of Myeloma Care | Marta Chesi, PhD & Erin Meermeier, PhD
- Boosting Infection Protection in Myeloma Patients with IvIG Therapy | Betsy O’Donnell, MD
- ICAHT After CAR-T for Myeloma: a Stem Cell Boost Solution | Carolina Schinke, MD
- CAR-T Therapy (ide-cel) Consolidation for Suboptimal ASCT Responders | Barry Paul, MD
- Looking Back: Real-World Data on CAR-T and Bispecifics for RRMM | Natalia Neparidze, MD
- CAR-T Efficacy for Myeloma Patients with Bispecific Exposure | Johannes Waldschmidt, MD
- Anito-Cel, a novel anti-BCMA CAR T-cell, for Relapsed/Refractory Myeloma | Ciara Freeman, MD
- Anti-BCMA CAR-T Resistance in Myeloma: Genomic Predictors | Francesco Maura, MD
- Genomic Determinants of Resistance to Anti-BCMA CAR-T Therapies in Myeloma | Ciara Freeman
- MRD Results from Cartitude-4 (Cilta-Cel vs SOC) in RRMM | Rakesh Popat
- Phase 1 Study of Antio-cel, an Anti-BCMA CAR-T, for RRMM | Michael Bishop, MD
- Late Complications and Long-term Care of CAR T-cell Patients | Michael Bishop, MD
- Minority Access & Outcomes with Anti-BCMA CAR T Therapy in Myeloma | Luca Paruzzo, MD
- Furthering Our Understanding of Delayed Neurotoxicity Post CAR-T in MM | Anupama Kumar, MD
- Delayed Neutrophil Recovery Following BCMA-Directed CAR-T in Myeloma | Zachary Avigan, MD
Event recordings
- The Efficacy of CAR-T Therapy in High-Risk Patients and Strategies to Improve Outcomes
- RESCHEDULED: Real-World CAR-T Data Update
- T-Cell Re-Direction Therapy | Bay Area RT March 9, 2024
- The History and Promise of CAR-T | Miami RoundTable April 20, 2024
- Using CAR-T Therapy Strategically in Myeloma Care | Charlotte Roundtable, May 4th, 2024
- The Evolving World of Immunotherapies | Detroit RoundTable October 12, 2024
- Relapsed/Refractory Multiple Myeloma | New York Roundtable October 19, 2024
- CAR-T Therapy in Multiple Myeloma | Dallas Roundtable November 2, 2024